Abstract
The oncoproteins MDM2 and MDMX negatively regulate the activity and stability of the p53 tumor suppressor, directly contributing to the development and progression of many tumors harboring wild type p53. Antagonizing MDM2 and MDMX to activate the p53 pathway has thus become an attractive new strategy for anticancer drug design. Several different classes of MDM2 and MDMX antagonists have been reported, including low molecular weight compounds, small peptides, miniature proteins, and peptidomimetics. This review aims to summarize the latest progress in the design of peptide activators of the p53 tumor suppressor.
Keywords: MDM2, MDMX, p53, D-peptide, peptidomimetics, mini-protein, proteins, helical, Hairpin, H-bonded, Nutlin-3, antagonists, D-enantiomer, hydrophobic
Current Pharmaceutical Design
Title: Peptide Activators of the p53 Tumor Suppressor
Volume: 17 Issue: 6
Author(s): Changyou Zhan and Wuyuan Lu
Affiliation:
Keywords: MDM2, MDMX, p53, D-peptide, peptidomimetics, mini-protein, proteins, helical, Hairpin, H-bonded, Nutlin-3, antagonists, D-enantiomer, hydrophobic
Abstract: The oncoproteins MDM2 and MDMX negatively regulate the activity and stability of the p53 tumor suppressor, directly contributing to the development and progression of many tumors harboring wild type p53. Antagonizing MDM2 and MDMX to activate the p53 pathway has thus become an attractive new strategy for anticancer drug design. Several different classes of MDM2 and MDMX antagonists have been reported, including low molecular weight compounds, small peptides, miniature proteins, and peptidomimetics. This review aims to summarize the latest progress in the design of peptide activators of the p53 tumor suppressor.
Export Options
About this article
Cite this article as:
Zhan Changyou and Lu Wuyuan, Peptide Activators of the p53 Tumor Suppressor, Current Pharmaceutical Design 2011; 17 (6) . https://dx.doi.org/10.2174/138161211795222577
DOI https://dx.doi.org/10.2174/138161211795222577 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Utilising Nanotechnology and Nanosystems for Treatment of Rare Diseases
Pharmaceutical Nanotechnology Rho GTPase Effector Functions in Tumor Cell Invasion and Metastasis
Current Drug Targets New Aspects of Regulatory Signaling Pathways and Novel Therapies in Pancreatic Cancer
Current Molecular Medicine Search and Rescue: Identification of Cannabinoid Actions Relevant for Neuronal Survival and Protection
Current Neuropharmacology Pharmacophores for Ligand Recognition and Activation / Inactivation of the Cannabinoid Receptors
Current Pharmaceutical Design Biological and Chemical Diversity of Coral-Derived Microorganisms
Current Medicinal Chemistry NK-1 Receptor Antagonists: A New Generation of Anticancer Drugs
Mini-Reviews in Medicinal Chemistry Recent Patents on Proteasome Inhibitors of Natural Origin
Recent Patents on Anti-Cancer Drug Discovery Natural Sourced Inhibitors of EGFR, PDGFR, FGFR and VEGFRMediated Signaling Pathways as Potential Anticancer Agents
Current Medicinal Chemistry Potential Anticancer Effect of Carvacrol Codrugs on Human Glioblastoma Cells
Current Drug Delivery Cell Cycle and Energy Metabolism in Tumor Cells: Strategies for Drug Therapy
Recent Patents on Anti-Cancer Drug Discovery Melatonin in the Biliary Tract and Liver: Health Implications
Current Pharmaceutical Design PARP1: A Promising Target for the Development of PARP1-based Candidates for Anticancer Intervention
Current Medicinal Chemistry Fluoride Effects: The Two Faces of Janus
Current Medicinal Chemistry Inhibitors of the TGF-β Superfamily and their Clinical Applications
Mini-Reviews in Medicinal Chemistry Production of Alpha Emitters for Targeted Alpha Therapy
Current Radiopharmaceuticals Small Interfering RNA for Effective Cancer Therapies
Mini-Reviews in Medicinal Chemistry Combining Gene Therapy and Radiation Against Cancer
Current Gene Therapy Nano-Enabled Drug Delivery in Cancer Therapy: Literature Analysis Using the MeSH System
Pharmaceutical Nanotechnology G and C Iterons and Strings in MicroRNAs Should be Important in Regulation of mRNAs<sup>†</sup>
MicroRNA